CClinicalTrials.gg
RecruitingNCT07824453Updated Sep 17, 2026

Nudge-Based Exercise Intervention for Adolescents With Obesity

An interventional study of Standard Exercise Intervention and Nudge-Based Exercise Intervention in Pediatric Obesity, sponsored by Nanjing Children's Hospital. Recruiting at 1 site in China. Open to participants aged 10 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Nanjing Children's Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
10 Years to 19 Years
Sex
All
01

Study summary

This study will evaluate whether a nudge-based exercise program can improve body mass index (BMI) and physical activity in adolescents with obesity. About 140 adolescents aged 10-19 years will participate. Participants will be placed into one of two groups according to the order in which they are admitted to the hospital. One group will receive a standard exercise intervention, while the other group will receive an 8-week nudge-based exercise program designed to make regular physical activity easier to start and maintain.

The nudge-based program uses simple behavioral strategies to make exercise easier to start and maintain, including framed and visual information, default exercise options, reminders, peer comparison and support, goal commitment, progress feedback, and small incentives. The program combines face-to-face sessions during hospitalization with home-based support, exercise tools, activity recording, and online follow-up.

The main outcomes are changes in BMI and physical activity. Other outcomes include body composition, blood metabolic markers, health-related quality of life, and exercise self-efficacy. Assessments will be conducted before and after the intervention, with follow-up assessments used to examine whether the effects are maintained over time.

02

Conditions studied

  • Pediatric Obesity

Browse trials for

03

Who can participate

Ages eligible
10 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged 10-19 years.
  • Body mass index (BMI) at or above the 95th percentile for age and sex according to the Chinese BMI screening criteria for overweight and obesity in children and adolescents.
  • Able to communicate and understand study instructions.
  • Willing to participate in the study and provide written informed consent, with informed consent from a parent or legal guardian as required.

Exclusion criteria

Exclusion Criteria:

  • Known secondary causes of obesity, including hypothalamic, endocrine, genetic, or syndromic obesity.
  • Use of anti-obesity medications, including injectable glucagon-like peptide-1 (GLP-1) receptor agonists, within 3 months before enrollment.
  • Severe cardiovascular or cerebrovascular disease, severe hepatic or renal dysfunction, or other serious organic diseases that may affect participation or study outcomes.
  • Psychiatric disorders or cognitive impairment that may interfere with participation or completion of study assessments.
  • Current participation in another weight-loss, structured exercise, or other intervention program that may affect body weight or physical activity.
  • Any contraindication to exercise or medical or physical condition that substantially limits participation in the prescribed exercise program.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Standard Exercise Intervention

    Participants in this arm receive a standardized exercise intervention based on current clinical guidance. The program focuses on moderate-intensity aerobic exercise performed 3-4 times per week for 40-50 minutes per session. Participants also receive routine exercise-related health education and follow-up support.

    Behavioral: Standard Exercise Intervention

  • Experimental
    Nudge-Based Exercise Intervention

    Participants in this arm receive an 8-week nudge-based exercise intervention designed to promote the initiation and maintenance of physical activity. The intervention uses strategies including framed and visual information, social reference, default exercise options, reminders, commitment, progress feedback, and incentives. It combines structured face-to-face sessions during hospitalization with an exercise nudge package and home-based support through online reminders, activity recording, peer interaction, and incentives.

    Behavioral: Nudge-Based Exercise Intervention

Interventions

  • BehavioralStandard Exercise Intervention

    Participants receive a standardized exercise program based on current clinical guidance. The program primarily consists of moderate-intensity aerobic exercise performed 3-4 times per week for 40-50 minutes per session. Participants also receive routine exercise-related health education and regular follow-up support.

  • BehavioralNudge-Based Exercise Intervention

    Participants receive an 8-week nudge-based exercise program designed to facilitate the initiation and maintenance of physical activity. The intervention incorporates framed and visual information, social reference, default exercise options, reduced effort for accessing exercise opportunities, reminders, commitment strategies, progress feedback, and incentives. During hospitalization, participants receive structured face-to-face sessions and an exercise nudge package containing exercise equipment, activity task cards, and a reminder device. After discharge, home-based support is provided through online exercise reminders, activity recording, peer interaction, progress feedback, and incentives.

05

What researchers measure

Primary outcomes

  1. Change in Body Mass Index (BMI)

    Body weight and height will be measured at baseline and approximately 3 months after baseline. Weight in kilograms and height in meters will be combined to report a single BMI value using the formula: BMI = weight (kg) / \[height (m)\]\^2. Body weight and height are component measurements used to derive BMI for this endpoint and are not separate outcome measures. Change in BMI will be calculated as the BMI value at approximately 3 months after baseline minus the baseline BMI value. The reported unit of measure is kg/m\^2.

    Time frame: Baseline and approximately 3 months after baseline

  2. Change in Physical Activity

    Physical activity will be assessed using the Chinese version of the International Physical Activity Questionnaire-Short Form (IPAQ-SF). The questionnaire records walking, moderate-intensity, and vigorous-intensity physical activity during the previous 7 days. The activity-specific values will be converted to metabolic equivalent of task minutes per week (MET-minutes/week) and summed according to the IPAQ-SF scoring method to generate a single total physical activity score. The individual activity categories are components of the total score and are not separate outcome measures under this endpoint. Change in physical activity from baseline to the follow-up assessment will be evaluated.

    Time frame: Baseline and approximately 3 months after baseline

Secondary outcomes

  1. Change in Total Sedentary Time

    Sedentary behavior will be assessed using a questionnaire that records time spent in common sedentary activities outside school hours on each day of a typical week, including screen-based activities, homework and reading, tutoring, motorized transportation, sedentary hobbies, social activities, and playing musical instruments. Total sedentary time will be summarized as average minutes per day. Change from baseline to follow-up will be evaluated.

    Time frame: Baseline and approximately 3 months after baseline

  2. Change in Body Fat Percentage

    Body fat percentage will be measured by bioelectrical impedance analysis using the InBody H30 body composition analyzer and reported as a percentage (%). Change from baseline to follow-up will be evaluated.

    Time frame: Baseline and approximately 3 months after baseline

  3. Change in Skeletal Muscle Mass

    Skeletal muscle mass will be measured by bioelectrical impedance analysis using the InBody H30 body composition analyzer and reported in kilograms (kg). Change from baseline to follow-up will be evaluated.

    Time frame: Baseline and approximately 3 months after baseline

  4. Change in Exercise Self-Efficacy

    Exercise self-efficacy will be assessed using the Exercise Self-Efficacy Scale (ESES), which evaluates participants' confidence in maintaining regular exercise when facing barriers such as fatigue, lack of time, or unfavorable weather. Higher scores indicate greater exercise self-efficacy. Change from baseline to follow-up will be evaluated.

    Time frame: Baseline and approximately 3 months after baseline

  5. Change in Health-Related Quality of Life

    Health-related quality of life will be assessed using the Chinese version of the Pediatric Quality of Life Inventory Generic Core Scales. The scale contains 23 items covering physical, emotional, social, and school functioning. Scores are transformed to a 0-100 scale, with higher scores indicating better health-related quality of life. Change in the total score from baseline to follow-up will be evaluated.

    Time frame: Baseline and approximately 3 months after baseline

Other outcomes

  1. Change in Fasting Blood Glucose

    Fasting blood glucose will be assessed by laboratory testing after an overnight fast. Change will be calculated as the follow-up value minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

  2. Change in Fasting Insulin

    Fasting insulin will be assessed by laboratory testing after an overnight fast. Change will be calculated as the follow-up value minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

  3. Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    Insulin resistance will be estimated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and fasting insulin concentrations. Higher values indicate greater insulin resistance. Change will be calculated as the follow-up value minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

  4. Change in Glycated Hemoglobin (HbA1c)

    Glycated hemoglobin (HbA1c) will be assessed by laboratory testing and reported as a percentage (%). Change will be calculated as the follow-up value minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

  5. Change in Total Cholesterol Concentration

    When available, total cholesterol concentration will be recorded from routine clinical laboratory testing performed during clinical re-examination and reported in millimoles per liter (mmol/L). Change from baseline will be calculated as the value at approximately 3 months after baseline minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

  6. Change in Triglyceride Concentration

    Triglyceride concentration will be recorded from routine clinical laboratory testing conducted as part of routine clinical re-examination and reported in millimoles per liter (mmol/L). No additional blood sample will be collected solely for this study. Change from baseline will be calculated as the value at approximately 3 months after baseline minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

  7. Change in Low-Density Lipoprotein Cholesterol (LDL-C) Concentration

    Low-density lipoprotein cholesterol (LDL-C) concentration will be recorded from routine clinical laboratory testing conducted as part of routine clinical re-examination and reported in millimoles per liter (mmol/L). No additional blood sample will be collected solely for this study. Change from baseline will be calculated as the value at approximately 3 months after baseline minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

  8. Change in High-Density Lipoprotein Cholesterol (HDL-C) Concentration

    High-density lipoprotein cholesterol (HDL-C) concentration will be recorded from routine clinical laboratory testing conducted as part of routine clinical re-examination and reported in millimoles per liter (mmol/L). No additional blood sample will be collected solely for this study. Change from baseline will be calculated as the value at approximately 3 months after baseline minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

  9. Change in Alanine Aminotransferase (ALT) Activity

    Alanine aminotransferase (ALT) activity will be recorded from routine clinical laboratory testing conducted as part of routine clinical re-examination and reported in units per liter (U/L). No additional blood sample will be collected solely for this study. Change from baseline will be calculated as the value at approximately 3 months after baseline minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

  10. Change in Aspartate Aminotransferase (AST) Activity

    Aspartate aminotransferase (AST) activity will be recorded from routine clinical laboratory testing conducted as part of routine clinical re-examination and reported in units per liter (U/L). No additional blood sample will be collected solely for this study. Change from baseline will be calculated as the value at approximately 3 months after baseline minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

  11. Change in Serum Uric Acid Concentration

    Serum uric acid concentration will be recorded from routine clinical laboratory testing conducted as part of routine clinical re-examination and reported in micromoles per liter (μmol/L). No additional blood sample will be collected solely for this study. Change from baseline will be calculated as the value at approximately 3 months after baseline minus the baseline value.

    Time frame: Baseline and approximately 3 months after baseline

06

Study locations

1 of 1 sites recruiting
  • Nanjing Children's Hospital
    Nanjing, Jiangsu, China
    • Chenxin Gan · Contact · gcx5101@163.com · 18205049751
    • Yubing Wang · Principal investigator
    Recruiting
07

Registry details

Key details

Study ID
NCT07824453
Lead sponsor
Nanjing Children's Hospital
Responsible party
Chenxin Gan (Graduate Student, Affiliated Hospital of Nanjing University of Chinese Medicine) — Principal investigator
First posted
Sep 17, 2026
Start date
Jul 1, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Chenxin Gan
Contact
gcx5101@163.com
18205049751
Yubing Wang
principal investigator · Nanjing Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion